Revelation Biosciences (NASDAQ:REVB) Issues Quarterly Earnings Results, Beats Estimates By $0.24 EPS

Revelation Biosciences (NASDAQ:REVB) issued its quarterly earnings data on Thursday. The company reported ($5.92) earnings per share for the quarter, topping the consensus estimate of ($6.16) by $0.24, FiscalAI reports.

Revelation Biosciences Price Performance

Shares of Revelation Biosciences stock traded up $0.33 during trading on Friday, hitting $3.89. The stock had a trading volume of 14,458 shares, compared to its average volume of 33,858. The firm’s fifty day simple moving average is $5.51 and its 200-day simple moving average is $7.90. The stock has a market cap of $2.66 million, a PE ratio of -0.05 and a beta of -0.13. Revelation Biosciences has a 12 month low of $3.08 and a 12 month high of $40.60.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, October 14th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.